HEADER TRANSCRIPTION 03-APR-15 4UIT TITLE BROMODOMAIN OF HUMAN BRD9 WITH 7-(3,4-DIMETHOXYPHENYL)-2-(4- TITLE 2 METHANESULFONYLPIPERAZINE-1-CARBONYL)-5-METHYL-4H,5H-THIENO-3,2-C- TITLE 3 PYRIDIN-4-ONE COMPND MOL_ID: 1; COMPND 2 MOLECULE: BROMODOMAIN-CONTAINING PROTEIN 9; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-TERMINAL BROMODOMAIN, RESIDUES 134-238; COMPND 5 SYNONYM: RHABDOMYOSARCOMA ANTIGEN MU-RMS-40.8, PROTEIN HUNK1, HUMAN COMPND 6 BRD4; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_PLASMID: PET26B KEYWDS TRANSCRIPTION, BRD9, INHIBITOR, HISTONE, EPIGENETIC READER, KEYWDS 2 BROMODOMAIN EXPDTA X-RAY DIFFRACTION AUTHOR C.CHUNG,N.T.THEODOULOU,P.BAMBOROUGH,P.G.HUMPHREYS REVDAT 3 15-MAY-19 4UIT 1 REMARK REVDAT 2 09-MAR-16 4UIT 1 JRNL REVDAT 1 22-APR-15 4UIT 0 JRNL AUTH N.H.THEODOULOU,P.BAMBOROUGH,A.J.BANNISTER,I.BECHER,R.A.BIT, JRNL AUTH 2 K.H.CHE,C.CHUNG,A.DITTMANN,G.DREWES,D.H.DREWRY,L.GORDON, JRNL AUTH 3 P.GRANDI,M.LEVERIDGE,M.LINDON,A.MICHON,J.MOLNAR,S.C.ROBSON, JRNL AUTH 4 N.C.O.TOMKINSON,T.KOUZARIDES,R.K.PRINJHA,P.G.HUMPHREYS JRNL TITL THE DISCOVERY OF I-BRD9, A SELECTIVE CELL ACTIVE CHEMICAL JRNL TITL 2 PROBE FOR BROMODOMAIN CONTAINING PROTEIN 9 INHIBITION. JRNL REF J.MED.CHEM. V. 59 1425 2016 JRNL REFN ISSN 0022-2623 JRNL PMID 25856009 JRNL DOI 10.1021/ACS.JMEDCHEM.5B00256 REMARK 2 REMARK 2 RESOLUTION. 1.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.6.0117 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 36.54 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 81.9 REMARK 3 NUMBER OF REFLECTIONS : 21959 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.153 REMARK 3 R VALUE (WORKING SET) : 0.152 REMARK 3 FREE R VALUE : 0.173 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1167 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.30 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.33 REMARK 3 REFLECTION IN BIN (WORKING SET) : 857 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 44.03 REMARK 3 BIN R VALUE (WORKING SET) : 0.1690 REMARK 3 BIN FREE R VALUE SET COUNT : 50 REMARK 3 BIN FREE R VALUE : 0.1820 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 821 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 33 REMARK 3 SOLVENT ATOMS : 207 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 13.53 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.13000 REMARK 3 B22 (A**2) : 0.06000 REMARK 3 B33 (A**2) : 0.22000 REMARK 3 B12 (A**2) : 0.04000 REMARK 3 B13 (A**2) : -0.14000 REMARK 3 B23 (A**2) : -0.52000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.053 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.054 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.027 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.196 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.969 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.964 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 912 ; 0.007 ; 0.019 REMARK 3 BOND LENGTHS OTHERS (A): 634 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 1242 ; 1.122 ; 1.946 REMARK 3 BOND ANGLES OTHERS (DEGREES): 1555 ; 0.852 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 112 ; 3.761 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 37 ;36.695 ;23.784 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 166 ;11.708 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 3 ;11.706 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 128 ; 0.065 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 980 ; 0.012 ; 0.022 REMARK 3 GENERAL PLANES OTHERS (A): 184 ; 0.005 ; 0.022 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A -10 A 9999 REMARK 3 ORIGIN FOR THE GROUP (A): -5.1599 7.0127 3.3259 REMARK 3 T TENSOR REMARK 3 T11: 0.0123 T22: 0.0076 REMARK 3 T33: 0.0065 T12: -0.0049 REMARK 3 T13: -0.0009 T23: 0.0019 REMARK 3 L TENSOR REMARK 3 L11: 0.5657 L22: 0.4104 REMARK 3 L33: 0.2301 L12: 0.0928 REMARK 3 L13: -0.0732 L23: 0.1843 REMARK 3 S TENSOR REMARK 3 S11: 0.0099 S12: -0.0439 S13: 0.0223 REMARK 3 S21: -0.0305 S22: -0.0012 S23: 0.0048 REMARK 3 S31: 0.0164 S32: -0.0076 S33: -0.0087 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 4UIT COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 03-APR-15. REMARK 100 THE DEPOSITION ID IS D_1290063534. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-SEP-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I02 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9200 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23127 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.300 REMARK 200 RESOLUTION RANGE LOW (A) : 36.540 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 81.9 REMARK 200 DATA REDUNDANCY : 1.900 REMARK 200 R MERGE (I) : 0.03000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 19.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.37 REMARK 200 COMPLETENESS FOR SHELL (%) : 51.8 REMARK 200 DATA REDUNDANCY IN SHELL : 1.90 REMARK 200 R MERGE FOR SHELL (I) : 0.05000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 12.70 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.24 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.42 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2M ZNAC, 20% PEG3350 20C, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 17 REMARK 465 ALA A 18 REMARK 465 GLU A 19 REMARK 465 ASN A 20 REMARK 465 GLU A 21 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLU A 30 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2019 O HOH A 2041 2.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2037 DISTANCE = 6.15 ANGSTROMS REMARK 525 HOH A2065 DISTANCE = 5.84 ANGSTROMS REMARK 525 HOH A2081 DISTANCE = 7.42 ANGSTROMS REMARK 525 HOH A2085 DISTANCE = 5.98 ANGSTROMS REMARK 525 HOH A2100 DISTANCE = 6.73 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE N1D A 1123 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4UIU RELATED DB: PDB REMARK 900 BROMODOMAIN OF HUMAN BRD9 WITH 7-(3,4-DIMETHOXYPHENYL )-N-(1,1- REMARK 900 DIOXO-1-THIAN-4-YL)-5-METHYL-4-OXO- 4H,5H-THIENO-3,2-C-PYRIDINE-2- REMARK 900 CARBOXAMIDE REMARK 900 RELATED ID: 4UIV RELATED DB: PDB REMARK 900 BROMODOMAIN OF HUMAN BRD9 WITH N-(1,1-DIOXO-1- THIAN-4-YL)-5-METHYL- REMARK 900 4-OXO-7-3-(TRIFLUOROMETHYL) PHENYL-4H,5H-THIENO-3,2-C-PYRIDINE-2- REMARK 900 CARBOXIMIDAMIDE REMARK 900 RELATED ID: 4UIW RELATED DB: PDB REMARK 900 BROMODOMAIN OF HUMAN BRD9 WITH N-(1,1-DIOXO-1- THIAN-4-YL)-5-ETHYL- REMARK 900 4-OXO-7-3-(TRIFLUOROMETHYL) PHENYL-4H,5H-THIENO-3,2-C-PYRIDINE-2- REMARK 900 CARBOXIMIDAMIDE REMARK 900 RELATED ID: 4UIX RELATED DB: PDB REMARK 900 N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 7-(3,4- DIMETHOXYPHENYL)- REMARK 900 N-(1,1-DIOXO-1-THIAN-4-YL)-5- METHYL-4-OXO-4H,5H-THIENO-3,2-C- REMARK 900 PYRIDINE-2- CARBOXAMIDE REMARK 900 RELATED ID: 4UIY RELATED DB: PDB REMARK 900 N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH N-(1,1- DIOXO-1-THIAN-4- REMARK 900 YL)-5-METHYL-4-OXO-7-3-( TRIFLUOROMETHYL)PHENYL-4H,5H-THIENO-3,2-C- REMARK 900 PYRIDINE-2 -CARBOXIMIDAMIDE REMARK 900 RELATED ID: 4UIZ RELATED DB: PDB REMARK 900 N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 7-(3,4- DIMETHOXYPHENYL)- REMARK 900 2-(4-METHANESULFONYLPIPERAZINE-1-CARBONYL )-5-METHYL-4H,5H-THIENO-3, REMARK 900 2-C-PYRIDIN-4-ONE DBREF 4UIT A 18 122 UNP A6NFY8 BRD9_HUMAN 134 238 SEQADV 4UIT GLY A 17 UNP A6NFY8 EXPRESSION TAG SEQRES 1 A 106 GLY ALA GLU ASN GLU SER THR PRO ILE GLN GLN LEU LEU SEQRES 2 A 106 GLU HIS PHE LEU ARG GLN LEU GLN ARG LYS ASP PRO HIS SEQRES 3 A 106 GLY PHE PHE ALA PHE PRO VAL THR ASP ALA ILE ALA PRO SEQRES 4 A 106 GLY TYR SER MET ILE ILE LYS HIS PRO MET ASP PHE GLY SEQRES 5 A 106 THR MET LYS ASP LYS ILE VAL ALA ASN GLU TYR LYS SER SEQRES 6 A 106 VAL THR GLU PHE LYS ALA ASP PHE LYS LEU MET CYS ASP SEQRES 7 A 106 ASN ALA MET THR TYR ASN ARG PRO ASP THR VAL TYR TYR SEQRES 8 A 106 LYS LEU ALA LYS LYS ILE LEU HIS ALA GLY PHE LYS MET SEQRES 9 A 106 MET SER HET N1D A1123 33 HETNAM N1D 7-(3,4-DIMETHOXYPHENYL)-5-METHYL-2-(4- HETNAM 2 N1D METHYLSULFONYLPIPERAZIN-1-YL)CARBONYL-THIENO[3,2- HETNAM 3 N1D C]PYRIDIN-4-ONE FORMUL 2 N1D C22 H25 N3 O6 S2 FORMUL 3 HOH *207(H2 O) HELIX 1 1 THR A 23 ARG A 38 1 16 HELIX 2 2 GLY A 56 ILE A 61 1 6 HELIX 3 3 ASP A 66 ALA A 76 1 11 HELIX 4 4 SER A 81 ASN A 100 1 20 HELIX 5 5 THR A 104 SER A 122 1 19 SITE 1 AC1 16 PHE A 44 PHE A 45 ILE A 53 ALA A 54 SITE 2 AC1 16 TYR A 99 ASN A 100 ARG A 101 TYR A 106 SITE 3 AC1 16 LYS A 111 HOH A2067 HOH A2074 HOH A2107 SITE 4 AC1 16 HOH A2185 HOH A2196 HOH A2204 HOH A2205 CRYST1 24.700 34.110 39.680 70.26 73.80 74.24 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.040486 -0.011426 -0.008888 0.00000 SCALE2 0.000000 0.030462 -0.009004 0.00000 SCALE3 0.000000 0.000000 0.027366 0.00000